Haizheng Pharmaceutical announced that the company plans to introduce the Dazzling Biologics patented technology platform for small nucleic acid development and RGN6669 products in the early pre-clinical stage, obtain exclusive global development, registration, production and commercialization rights for cooperative products, and become a drug marketing license holder. The initial payment for this transaction was 10 million yuan, the cumulative development milestones of the first batch of cooperation targets and RGN6669 products did not exceed 348 million yuan, and the cumulative sales milestones did not exceed 630 million yuan. In addition, sales equity payments were required. This transaction does not constitute a related transaction or major asset restructuring. The relevant bill will be submitted to the 4th Extraordinary Shareholders' Meeting in 2026 for consideration.

Haizheng Pharmaceutical announced that the company plans to introduce the Dazzling Biologics patented technology platform for small nucleic acid development and RGN6669 products in the early pre-clinical stage, obtain exclusive global development, registration, production and commercialization rights for cooperative products, and become a drug marketing license holder. The initial payment for this transaction was 10 million yuan, the cumulative development milestones of the first batch of cooperation targets and RGN6669 products did not exceed 348 million yuan, and the cumulative sales milestones did not exceed 630 million yuan. In addition, sales equity payments were required. This transaction does not constitute a related transaction or major asset restructuring. The relevant bill will be submitted to the 4th Extraordinary Shareholders' Meeting in 2026 for consideration.